Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Coronavirus: fears the virus is learning how to resist vaccines

Coronavirus: fears the virus is learning how to resist vaccines

US company Novavax reported that its vaccine was nearly 90 per cent effective in clinical trials in Britain, but the figure fell to 49 per cent in South Africa.

New data showing that two Covid-19 vaccines are far less effective in South Africa than in other places they were tested have heightened fears that the coronavirus is quickly finding ways to elude the world’s most powerful tools to contain it.

The US company Novavax reported this week that although its vaccine was nearly 90 per cent effective in clinical trials conducted in Britain, the figure fell to 49 per cent in South Africa – and that nearly all the infections the company analysed in South Africa involved the B. 1.351 variant that emerged there late last year and has spread to the United States and at least 30 other countries.

Johnson & Johnson announced on Friday that its new shot was 72 per cent effective against preventing moderate or severe illness in the United States, compared with 66 per cent in Latin America and 57 per cent in South Africa.

Laboratory tests had suggested that the vaccines authorised in the US – one from Pfizer and BioNTech, the other from Moderna and the National Institutes of Health – trigger a smaller immune response to the South Africa variant.

Now there is evidence from tests in people that some variants are less vulnerable to certain vaccines.

“From an evolutionary biology perspective, this is totally expected and anticipated,” said Dr Michael Mina, a Harvard epidemiologist. “But it never feels good to be validated on something so scary.”

Researchers once believed it would take several more months, or even years, for the virus to develop resistance to vaccines. They said the speedy evolution is largely a result of the virus’ unchecked spread.

More than 100 million people have been infected worldwide, and each of those infections is an opportunity for the virus to randomly mutate.

A mutation that happens to give the virus an advantage – the ability to resist the body’s natural defences, for example – can become the basis for a heartier variant.

One early sign that this process was under way was the significant number of people who were contracting the coronavirus a second time. It appeared that the training their immune systems received during the first infection was failing to protect them from new versions of the virus.

Scientists at Moderna and Pfizer-BioNTech worried that the same thing could happen with immunity induced by their vaccines. In laboratories, they took several versions of the virus and exposed them to blood samples from a small number of people who had been vaccinated.

The neutralising antibodies produced in response to Moderna’s vaccine were equally effective against the original coronavirus and the B.1.1.7 strain that emerged in the United Kingdom but were far less effective against the South Africa strain. Pfizer’s vaccine was only slightly less effective against the South Africa variant compared with the others.

Experts had cautioned that laboratory tests were an imperfect model for understanding the immune response in people.

Other parts of the immune system, such as T-cells, might play a role in fighting a variant, even when neutralising antibodies fall short, said Marc Lipsitch, a Harvard epidemiologist.

That is why the Novavax trial – the first to test the interactions between variants and vaccines in the real world – was so concerning.

“Whether people who have been vaccinated get infected with the variant – that’s the real proof in the pudding,” said Dr Otto Yang, an infectious-disease researcher at UCLA.

Novavax cautioned that its South Africa study, which included about 4,400 patients, was too small to offer a precise measurement on the vaccine’s efficacy.

The Johnson & Johnson results provided further evidence that the problem was serious.

Experts said the weaker performance of the vaccine in South Africa – where it was tested on about 6,500 people – almost certainly was a result of the predominance of the variant circulating widely there. Researchers believe that it is more contagious than other variants and that it has become more common in South Africa and elsewhere since the trial began in September.

Researchers said variants were also likely to blame for the subpar showing of the Johnson & Johnson vaccine in Latin America – where it was tested in more than 17,000 people in Argentina, Brazil, Chile, Colombia, Mexico and Peru.

The mutations of greatest concern are on the spike protein on the surface of the virus, because the current crop of vaccines train the immune system to recognise that protein. Mutations there increase the likelihood that the virus will slip by undetected.


Dr Rochelle Walensky, director of the Centres for Disease Control and Prevention


Mina, the Harvard epidemiologist, likened the process to searching for a criminal by memorising the appearance of only his nose and mouth. At first, this may prove sufficient. But if the criminal gets a nose job, investigators will wish they learned about his eyes, ears and hair as well.

Mina said a more diverse arsenal of vaccines, employing a variety of approaches, is needed.

In the meantime, Moderna has announced efforts to develop a booster shot to add to its current two-shot regimen to fend off the South Africa variant. The company also plans to test whether a third shot of the original formula could help with other strains.

BioNTech, the company that worked with Pfizer on its shot, is also considering developing an adjusted vaccine.

The United States reported its first known cases of the South Africa variant on Thursday, in two people in South Carolina. The UK strain, which is also thought to be more contagious, is also circulating there.


Director of the National Institute of Allergy and Infections Diseases Anthony Fauci


In a briefing for reporters Friday, Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the confirmation that more transmissible strains are now in the US is a “wake-up call” that underscores the need to rapidly vaccinate Americans.

“Vaccinating as many people as we can, as quickly as we can” is the key to slowing the ability of the virus to mutate, he said. “Viruses cannot mutate if they cannot replicate.”

The US is vaccinating an average of 1.2 million people a day, said Dr Rochelle Walensky, director of the Centres for Disease Control and Prevention.

Experts say that is far too slow, because there’s no knowing what kind of advanced variants will exist by the time the vaccination campaign reaches critical mass.

They stress that vaccination must be accompanied by defensive tactics such as masking and social distancing until case numbers are negligibly low.

“If you think you’re going to simply vaccinate your way out of this, it’s going to be like whack-a-mole,” said Susan Butler-Wu, director of clinical microbiology at LA County-USC Medical Center.

An effective vaccination campaign must eventually stretch around the world. If an impressive strain were to pop up next year in, for example, Brazil, even a fully vaccinated US could be in danger.

“You can vaccinate the hell out of America,” said Mina, but “until everyone is protected, we’re all still at risk.”

Fauci called for bolstering the government’s ability to detect new viral mutations. Genetic sequencing efforts have been fragmented, relying on academics and other groups to voluntarily upload their findings. The US sequences just 1 per cent of the millions of positive samples collected during routine coronavirus testing.

“We’re shining a flashlight around in the dark, hoping we spot dangerous variants,” said Anne Rimoin, an epidemiologist at UCLA. “What we really need to do is flip on the lights.”

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
House Republicans Move to Defund OECD Over Global Tax Dispute
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
Intel Reports Revenue Beats but Sees 81% Rise in Losses
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
CEO Resigns Amid Controversy Over Relationship with HR Executive
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
Tulsi Gabbard Unveils Evidence Alleging Political Manipulation of Intelligence During Trump Administration
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Trump Announces Coca-Cola to Shift to Cane Sugar in U.S. Production
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Air India Pilot’s Mental Health Records Under Scrutiny
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
Moonshot AI Unveils Kimi K2: A New Open-Source AI Model
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Bitcoin Reaches New Milestone of $116,000
Severe Heatwave Claims 2,300 Lives Across Europe
Declining Beer Consumption Signals Cultural Shift in Germany
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
Western Europe Records Hottest June on Record
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
China’s Central Bank Consults European Peers on Low-Rate Strategies
France Requests Airlines to Cut Flights at Paris Airports Amid Planned Air Traffic Controller Strike
Poland Implements Border Checks Amid Growing Migration Tensions
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
×